Treatment and prevention of Pneumocystis pneumonia in patients without HIV

Authors:: Charles F Thomas, Jr, MD; Andrew H Limper, MD
Section Editor:: John W Baddley, MD, MSPH
Deputy Editor:: Milana Bogorodskaya, MD

Literature review current through: Mar 2023. | This topic last updated: Nov 30, 2022.

INTRODUCTION — Pneumocystis pneumonia (PCP) is a potentially life-threatening infection that occurs in immunocompromised individuals. The nomenclature for the species of Pneumocystis that infects humans has been changed from Pneumocystis carinii to Pneumocystis jirovecii; this was done to distinguish it from the species that infects rats.

Patients with human immunodeficiency virus (HIV) and a low CD4 count are at the highest risk of PCP. Others at substantial risk include immunocompromised patients, such as hematopoietic stem cell and solid organ transplant recipients receiving immunosuppressant agents, those with cancer (particularly hematologic malignancies), and those receiving glucocorticoids, chemotherapeutic agents, and other immunosuppressive medications.

The treatment and prophylaxis of PCP in patients without HIV infection will be reviewed here. PCP in patients with HIV and the epidemiology, clinical manifestations, and diagnosis of PCP in patients without HIV are discussed separately. (See "Treatment and prevention of Pneumocystis infection in patients with HIV" and "Epidemiology, clinical manifestations, and diagnosis of Pneumocystis pneumonia in patients without HIV".)

TREATMENT

Trimethoprim-sulfamethoxazole — We recommend trimethoprim-sulfamethoxazole (TMP-SMX) as the treatment of choice for PCP of any severity in patients without HIV (table 1) [1]. The dose of TMP-SMX for patients with normal renal function is 15 to 20 mg/kg (dosing is based upon the TMP component and expressed as mg/kg per day of TMP) intravenously or orally daily in three or four divided doses. Dose may need to be adjusted if creatinine clearance changes during therapy. Patients should receive intravenous therapy until they are clinically stable (eg, PaO₂ ≥60 mmHg, respiratory rate <25) and have a functioning gastrointestinal tract. For renal dose adjustment recommendations, refer to TMP-SMX drug information.

For patients with allergy to TMP-SMX, desensitization should ideally be performed since TMP-SMX is the most effective regimen. However, if the patient has a history of a severe allergy (eg, Stevens-Johnson syndrome, toxic epidermal necrolysis), TMP-SMX should be avoided and desensitization should not be performed. (See "Treatment and prevention of Pneumocystis infection in patients with HIV", section on 'Desensitization for patients with a sulfa allergy' and "Sulfonamide allergy in HIV-uninfected patients".)

Large randomized trials have proven the efficacy of TMP-SMX in patients with HIV infection, whereas efficacy in patients without HIV infection has only been shown in a few small observational studies [2-4] and one comparative randomized trial [5]. (See "Treatment and prevention of Pneumocystis infection in patients with HIV".)

Some patients receiving TMP-SMX experience hyperkalemia, particularly those with renal insufficiency, older patients, those concurrently receiving other drugs that promote hyperkalemia, those receiving high doses of TMP-SMX, and those with disorders of potassium metabolism. Accordingly, we recommend monitoring potassium levels before and periodically after the institution of TMP-SMX therapy. Other adverse effects are discussed in greater detail separately. (See "Trimethoprim-sulfamethoxazole: An overview", section on 'Adverse effects and precautions'.)

Alternative agents by severity of disease — Alternative drugs for the treatment of PCP have been studied primarily in patients with HIV. Regimens that may be used for PCP when TMP-SMX cannot be used include clindamycin plus primaquine, trimethoprim plus dapsone, atovaquone, and intravenous (IV) pentamidine; dosing of these agents is summarized in the table (table 1). The choice of regimen in patients who cannot take TMP-SMX depends in part upon the severity of disease.

●For mild disease, options include:

•Atovaquone

•Clindamycin plus primaquine

•TMP plus dapsone

All of these agents can be given orally. Although there are limited data, we prefer oral atovaquone in patients with mild disease.

●For moderate disease, options include:

•Clindamycin plus primaquine

•TMP plus dapsone

Although there are limited data, we prefer clindamycin plus primaquine for patients with moderate disease.

●For severe disease, options include:

•Clindamycin plus primaquine

•Intravenous pentamidine

Clindamycin can be given intravenously, but primaquine is available only as an oral formulation. Pentamidine should be given intravenously.

For severe disease, we prefer intravenous clindamycin plus oral primaquine because this regimen is less toxic than IV pentamidine. Patients should receive clindamycin intravenously until they are clinically stable (eg, PaO₂ ≥60 mmHg, respiratory rate <25) and have a functioning gastrointestinal tract, at which point they can be switched to oral clindamycin. The efficacy of clindamycin plus primaquine was illustrated in a meta-analysis of salvage treatment of 456 patients with HIV and 41 patients without HIV who had confirmed PCP but did not improve with conventional antipneumocystis therapy (most commonly TMP-SMX or IV pentamidine) [6]. The combination of clindamycin plus primaquine was the most effective alternative treatment in such patients. (See "Treatment and prevention of Pneumocystis infection in patients with HIV".)

IV pentamidine is not often used because it is associated with substantial toxicity (eg, hypotension, hypoglycemia, nephrotoxicity, and pancreatitis) and must be administered parenterally. In a randomized trial of 50 patients with PCP, IV pentamidine (4 mg/kg once daily) was as effective as TMP-SMX [5].

Patients should be tested for glucose-6-phosphate dehydrogenase deficiency before taking dapsone or primaquine. (See "Treatment and prevention of Pneumocystis infection in patients with HIV".)

The cyst wall of P. jirovecii contains beta-D-glucan, the synthesis of which is inhibited by echinocandins (eg, caspofungin) [7]. The role for echinocandins in treating or preventing PCP in humans is not established. Case reports of progression of disease in patients receiving echinocandins have been published [8].

Duration of therapy — The duration of therapy for PCP in patients without HIV infection has not been adequately studied. Given the fulminant presentation and poor outcomes in patients without HIV [9], we suggest treating for 21 days. These recommendations have been extrapolated from the recommended duration of therapy for patients with HIV infection, who have a greater risk of relapse with 14 than 21 days of therapy, and who have a greater organism burden and slower clinical response than patients without HIV [9,10]. (See 'Outcomes' below and "Epidemiology, clinical manifestations, and diagnosis of Pneumocystis pneumonia in patients without HIV", section on 'Clinical manifestations'.)

Patients without HIV who have PCP should start to show clinical improvement by the seventh day of therapy. Patients who are not improving after seven days of therapy may require re-evaluation to look for other coinfections. If no other explanation is found, these patients should be considered to have treatment failure and are treated in the same way as patients with HIV who fail initial therapy. (See "Treatment and prevention of Pneumocystis infection in patients with HIV", section on 'Treatment failure'.)

Patients are usually symptomatically better after 21 days of therapy for PCP. A clinician with expertise in the management of PCP (eg, an infectious diseases specialist) should be consulted to assist with the management of patients with severe or protracted illness despite appropriate therapy.

After completing the course of treatment, patients should be considered for antimicrobial therapy at a reduced dose to prevent recurrent infection (ie, secondary prophylaxis). The antimicrobial regimens used for secondary prophylaxis are the same as those used to prevent initial infection and are described below. (See 'Regimens' below.)

Adjunctive glucocorticoids — Adjunctive glucocorticoids are recommended in patients with HIV and moderate or severe PCP because their use improves clinical outcomes and mortality without increasing the risk of other opportunistic infections. (See "Treatment and prevention of Pneumocystis infection in patients with HIV", section on 'Use of corticosteroids'.)

Given the fulminant course and high mortality with moderate to severe PCP in patients without HIV, we suggest the use of glucocorticoid therapy in patients with PCP who, while breathing room air, have an arterial blood gas measurement that shows a partial pressure of oxygen <70 mmHg or an alveolar-arterial (A-a) oxygen gradient ≥35 mmHg, or hypoxemia on pulse oximetry (eg, room air oxygen saturation <92 percent). Patients who worsen clinically and meet criteria for glucocorticoids while receiving anti-Pneumocystis therapy are also candidates for adjunctive glucocorticoids. The glucocorticoid regimen is shown in the table (table 1). (See "Treatment and prevention of Pneumocystis infection in patients with HIV", section on 'Corticosteroid regimen'.)

Patients who do not meet the above criteria for glucocorticoid therapy but are receiving glucocorticoids for some other reason (eg, graft-versus-host disease) should continue their current regimen.

In contrast to patients with HIV, there are limited data on the efficacy of adjunctive glucocorticoids for the treatment of PCP in patients without HIV. The available limited data do not provide support for the routine use of adjunctive glucocorticoids in patients without HIV but with PCP who have mild to moderate disease. In a retrospective cohort study evaluating the outcomes of 323 hospitalized patients without HIV who had P. jirovecii pneumonia, there were no differences in mortality, length of stay, admission to the intensive care unit, or need for mechanical ventilation in the 258 patients who received adjunctive corticosteroids versus the 65 who did not [11]. A second retrospective study of 31 patients without HIV but with PCP also found no difference in the need for mechanical ventilation or mortality between the glucocorticoid-treated and -untreated groups [12].

However, in severe disease, data suggest adjunctive glucocorticoids may be beneficial. In a meta-analysis of 16 retrospective observational studies that includes over 2500 cases of PCP in patients without HIV, corticosteroids were associated with lower mortality in those with respiratory failure (odds ratio 0.63, 95% CI 0.41-0.95) [13]. In one of the retrospective studies included in the meta-analysis that looked at 30 patients without HIV but with severe PCP, 16 patients who received the equivalent of ≥60 mg of prednisone per day had a significantly shorter duration of mechanical ventilation, intensive care unit admission, and supplemental oxygenation than the 14 patients who received the equivalent of ≤30 mg of prednisone per day or were on a glucocorticoid taper [14]. However, similar rates of mechanical ventilation and in-hospital mortality were observed. It remains unclear whether corticosteroids are beneficial, however, the greater degree of inflammation in the lungs of patients without HIV provides some rationale for glucocorticoid therapy [9].

OUTCOMES — In the absence of appropriate antibiotic therapy, the mortality from PCP in patients without HIV is 90 to 100 percent [2]. In treated patients, the outcomes in those without HIV are generally worse than in patients with HIV; mortality from PCP in patients with HIV infection is approximately 10 to 20 percent compared with 35 to 50 percent in those without HIV [10,15-18]. Patients with cancer have the highest mortality [10,19]. Patients without HIV who have PCP also have higher rates of hospitalization and intensive care unit admission [16].

Severe PCP is associated with higher mortality [16,20]. As an example, in a retrospective review of 30 patients without HIV but with PCP and respiratory failure, the mortality was 67 percent [20]. Mortality was associated with an elevated APACHE III score on the day of intensive care unit admission, delay in intubation, duration of mechanical ventilation, and the development of pneumothorax [20]. (See "Predictive scoring systems in the intensive care unit", section on 'Acute Physiologic and Chronic Health Evaluation (APACHE)'.)

INFECTION CONTROL — Hospitalized patients with PCP should be cared for with standard precautions, although they should not be placed in the same room with other immunocompromised individuals due to the potential for person-to-person transmission [21].

PROPHYLAXIS

Indications — The risk for PCP is determined by the degree of cell-mediated immune deficiency and can occur due to immunocompromising conditions or receipt of immunosuppressive agents. The number of drugs associated with increased risk for PCP is constantly expanding; the more commonly used ones are listed below. In general, PCP prophylaxis should be considered in patients receiving drugs associated with lymphodepletion that are likely to cause significant defects in cell-mediated immune deficiency.

We recommend PCP prophylaxis for:

●Patients with certain primary immunodeficiencies (eg, severe combined immunodeficiency, idiopathic CD4 T-lymphocytopenia, hyper-immunoglobulin [Ig]M syndrome) [22,23].

●Patients with acute lymphocytic leukemia [24].

●Solid organ transplant recipients, often for at least six months to one year following transplantation and during periods of high doses of immunosuppressive medications (eg, during treatment for acute rejection) [25]; lung transplant recipients typically receive lifelong prophylaxis. (See "Prophylaxis of infections in solid organ transplantation", section on 'Pneumocystis pneumonia' and "Fungal infections following lung transplantation", section on 'Pneumocystis jirovecii'.)

●Allogeneic hematopoietic cell transplant (HCT) recipients beginning after engraftment and continuing for as long as immunosuppressive therapy is given; the typical duration of PCP prophylaxis is six months in allogeneic HCT recipients but is longer in those requiring treatment for graft-versus-host disease [24,26]. This is discussed in detail elsewhere. (See "Prevention of infections in hematopoietic cell transplant recipients", section on 'Pneumocystis prophylaxis'.)

●Selected autologous HCT recipients, including those who have an underlying hematologic malignancy, such as lymphoma, myeloma, or leukemia, especially when intensive treatment or conditioning regimens have included a purine analog (eg, fludarabine, cladribine) or high-dose glucocorticoids [24,26]. This is discussed in detail elsewhere. (See "Prevention of infections in hematopoietic cell transplant recipients", section on 'Pneumocystis prophylaxis'.)

●Patients receiving a glucocorticoid dose equivalent to ≥20 mg of prednisone daily for one month or longer who also have another cause of immunocompromise (eg, certain hematologic malignancies or a second immunosuppressive drug) [1,17,24,27-34].

●Patients receiving phosphatidylinositol 3-kinase inhibitors (eg, idelalisib and ibrutinib) [35-38]. (See "Prevention of infections in patients with chronic lymphocytic leukemia", section on 'Bruton tyrosine kinase and phosphatidylinositol 3-kinase inhibitors'.)

●Patients receiving alkylating agents, such as a purine analog (eg, cladribine, fludarabine) alone, or triazenes (eg, temozolomide) if used concurrently with steroids or radiotherapy [24,39]. (See "Prevention of infections in patients with chronic lymphocytic leukemia", section on 'Purine analog-cyclophosphamide combination therapy'.)

●Patients receiving certain monoclonal antibodies that cause lymphodepletion (eg, anti-CD52, anti-CCR4, anti-SLAMF [signaling lymphocyte activation molecule family], polatuzumab vedotin).

•Patients receiving an anti-CD52 monoclonal antibody (eg, alemtuzumab) should receive PCP prophylaxis for a minimum of two months after completion of therapy or until the CD4 count is >200 cells/microL, whichever occurs later [24,40].

•Patients receiving an anti-CD20 monoclonal antibody (eg, rituximab) or a checkpoint inhibitor (eg, pembrolizumab, nivolumab, durvalumab) with or without concurrent glucocorticoid should also receive PCP prophylaxis [41].

Data are limited to support a broad recommendation for PCP prophylaxis in patients receiving many other immunomodulatory agents, including:

●Janus-associated kinase inhibitors (eg, tofacitinib, baricitinib, upadacitinib).

●Mammalian target of rapamycin inhibitors (eg, temsirolimus, everolimus) [42].

When deciding whether to administer PCP prophylaxis in patients receiving these agents, clinicians should consider the underlying condition, presence of other concomitant immunosuppressive drugs (eg, glucocorticoids), duration of therapy, and the patient’s comorbidities (eg, lung function). Presence of underlying lung disease (eg, pulmonary fibrosis) may increase risk of PCP [43].

Guidelines have been published for the use of PCP prophylaxis in patients with cancer, including HCT recipients [44-48], as well as in solid organ transplant recipients [49]. There are no published guidelines for PCP prophylaxis among patients with rheumatologic or dermatologic diseases receiving immunosuppressive drugs, but some advocate its use in such patients when they are receiving high-dose immunosuppressive therapy [50-53].

In a meta-analysis of randomized trials of PCP prophylaxis in immunocompromised patients without HIV infection, the authors concluded that prophylaxis is warranted when the risk of PCP is higher than 6 percent [54].

PCP prophylaxis should be considered in patients with other conditions that cause immunocompromise based upon their risk of PCP. (See "Epidemiology, clinical manifestations, and diagnosis of Pneumocystis pneumonia in patients without HIV", section on 'Risk factors'.)

Regimens — Trimethoprim-sulfamethoxazole (TMP-SMX) is the recommended first-line agent for PCP prophylaxis based upon its proven efficacy (table 2) [1,24,26,27,29,54]. For patients with normal renal function, it may be given as one double-strength tablet daily or three times per week or as one single-strength tablet daily. For renal dose adjustment recommendations, see TMP-SMX drug information. For those who are intolerant of TMP-SMX, desensitization should be attempted when possible. Although leukopenia and agranulocytosis are reported side effects of TMP-SMX, from our experience, patients who initiate TMP-SMX after neutrophil recover tend to do well. TMP-SMX also prevents Toxoplasma gondii infections as well as some bacterial infections, such as pneumococcal, nocardial, and listerial infections. Some clinicians have been hesitant to use TMP-SMX for PCP prophylaxis in patients receiving methotrexate due to concern for myelosuppression. However, prophylactic doses of TMP-SMX appear to be safe in patients with granulomatosis with polyangiitis (GPA) receiving methotrexate [34,55]. (See "Treatment and prevention of Pneumocystis infection in patients with HIV", section on 'Desensitization for patients with a sulfa allergy' and "Sulfonamide allergy in HIV-uninfected patients".)

For patients who cannot take TMP-SMX, we suggest either dapsone (with pyrimethamine if Toxoplasma prophylaxis is indicated) or atovaquone. For patients in whom hematologic toxicity is a concern (eg, HCT recipients), we favor atovaquone because dapsone can cause agranulocytosis and hemolytic anemia. For patients in whom hematologic toxicity is not a concern, we prefer dapsone because it is less expensive than atovaquone. Patients should be tested for glucose-6-phosphate dehydrogenase deficiency before taking dapsone.

Another alternative for PCP prophylaxis is aerosolized pentamidine. However, we rarely use aerosolized pentamidine because it is less effective than the other regimens, requires special equipment, and has been associated with transmission of Mycobacterium tuberculosis. In addition, it is only effective locally; if dispersal of the aerosol does not reach all portions of the lungs, untreated areas remain at risk for PCP. (See "Treatment and prevention of Pneumocystis infection in patients with HIV", section on 'Patients with a sulfa allergy'.)

PCP prophylaxis should be continued until the risk factor for the disease is no longer present [24,26,27]. (See 'Indications' above.)

Caution should be exercised in discontinuation of PCP prophylaxis in patients who have received high-dose glucocorticoids and/or cyclophosphamide, since prolonged immunosuppression may persist after discontinuation of such agents. Although the CD4 count has not been shown to correlate with risk of PCP in patients without HIV, some experts have suggested discontinuing prophylaxis only in patients who have had a CD4 count >200 cells/microL for at least six months [31].

Some data suggest that sulfonamide-containing antibiotics, including TMP-SMX, can cause exacerbations of systemic lupus erythematosus (SLE), particularly in patients with adverse reactions to these agents. As a result, many rheumatologists avoid TMP-SMX prophylaxis in patients with SLE. We suggest atovaquone as an alternative agent in such patients who require PCP prophylaxis (table 2). (See "Overview of the management and prognosis of systemic lupus erythematosus in adults", section on 'Issues with specific therapies'.)

PCP prophylaxis in hematopoietic cell transplant recipients and lung transplant recipients is discussed in detail separately. (See "Prevention of infections in hematopoietic cell transplant recipients", section on 'Pneumocystis prophylaxis' and "Fungal infections following lung transplantation", section on 'Pneumocystis pneumonia'.)

Efficacy — PCP prophylaxis with TMP-SMX is highly effective, and it is therefore considered the first-line agent. This approach has been recommended in several guidelines by major organizations [1,24,26,27]. In a retrospective study from Denmark that identified 50 cases of PCP in patients without HIV infection during 2002 to 2004, the majority of patients (82 percent) never received PCP prophylaxis, whereas 16 percent had PCP prophylaxis discontinued months prior to diagnosis [56].

Trimethoprim-sulfamethoxazole — The effectiveness of TMP-SMX prophylaxis was illustrated in a meta-analysis of 13 randomized controlled trials that included 1412 immunocompromised patients without HIV infection who had undergone autologous hematopoietic cell or solid organ transplantation or had a hematologic malignancy [54]. TMP-SMX prophylaxis was associated with an 85 percent reduction in the occurrence of PCP compared with no prophylaxis or fluoroquinolone prophylaxis, which is inactive against Pneumocystis (relative risk [RR] 0.15, 95% CI 0.04-0.62). The number needed to treat to prevent one infection was 19. Mortality due to PCP was also significantly reduced (RR 0.17, 95% CI 0.03-0.94), although all-cause mortality was not. Using data from two trials, no differences in efficacy were found between once-daily and thrice-weekly administration schedules for TMP-SMX.

A cost-effectiveness analysis in patients with GPA receiving immunosuppressive drugs suggested that PCP prophylaxis with TMP-SMX increased quality-adjusted life expectancy and reduced costs [57].

TMP-SMX is generally well tolerated in patients without HIV infection, as the meta-analysis described above found that adverse events necessitating cessation of therapy (leukopenia, thrombocytopenia, severe dermatologic reactions) occurred in only 3.1 percent of adults [54]. In contrast, TMP-SMX has a high rate of adverse effects in patients with HIV. (See "Treatment and prevention of Pneumocystis infection in patients with HIV", section on 'Patients without a sulfa allergy'.)

Other drugs — Other drugs that can been used for PCP prophylaxis in patients without HIV include atovaquone, dapsone with or without pyrimethamine, and aerosolized pentamidine (table 2).

Randomized trials in patients without HIV are limited [58,59]. One such trial that compared atovaquone with TMP-SMX for PCP prophylaxis in 39 patients following autologous hematopoietic cell transplantation showed that atovaquone is well tolerated in this patient population [58]. No firm conclusions can be reached about the relative efficacy of atovaquone since the number of patients studied was small and no patient in either arm developed PCP.

The comparative efficacy of PCP prophylaxis regimens has been more extensively studied in patients with HIV. (See "Treatment and prevention of Pneumocystis infection in patients with HIV", section on 'Regimens for prophylaxis'.)

SOCIETY GUIDELINE LINKS — Links to society and government-sponsored guidelines from selected countries and regions around the world are provided separately. (See "Society guideline links: Pneumocystis pneumonia in patients without HIV".)

INFORMATION FOR PATIENTS — UpToDate offers two types of patient education materials, "The Basics" and "Beyond the Basics." The Basics patient education pieces are written in plain language, at the 5^th to 6^th grade reading level, and they answer the four or five key questions a patient might have about a given condition. These articles are best for patients who want a general overview and who prefer short, easy-to-read materials. Beyond the Basics patient education pieces are longer, more sophisticated, and more detailed. These articles are written at the 10^th to 12^th grade reading level and are best for patients who want in-depth information and are comfortable with some medical jargon.

Here are the patient education articles that are relevant to this topic. We encourage you to print or email these topics to your patients. (You can also locate patient education articles on a variety of subjects by searching on "patient info" and the keyword(s) of interest.)

●Basics topic (see "Patient education: Pneumocystis pneumonia (The Basics)")

SUMMARY AND RECOMMENDATIONS

●Treatment

•Preferred regimen − We recommend trimethoprim-sulfamethoxazole (TMP-SMX) as the preferred medication for the treatment of Pneumocystis pneumonia (PCP) in patients without HIV (table 1) (Grade 1B). The dose of TMP-SMX for patients with normal renal function is 15 to 20 mg/kg (dosing is based upon the TMP component and expressed as mg/kg per day of TMP) intravenously or orally daily in three or four divided doses. The usual duration of therapy is 21 days. (See 'Trimethoprim-sulfamethoxazole' above and 'Duration of therapy' above.)

•Alternative regimens − For patients with allergy to TMP-SMX, desensitization should ideally be performed since TMP-SMX is the most effective regimen. Exceptions include patients with a history of a severe allergy (eg, Stevens-Johnson syndrome, toxic epidermal necrolysis). In these cases, TMP-SMX should be avoided and desensitization should not be performed. Alternative regimens for treatment of PCP are discussed above. (See 'Trimethoprim-sulfamethoxazole' above and 'Alternative agents by severity of disease' above.)

•Adjunctive glucocorticoids − We suggest using adjunctive glucocorticoids in patients without HIV who, while breathing room air, have an arterial blood gas measurement that shows a partial pressure of oxygen <70 mmHg or an alveolar-arterial (A-a) oxygen gradient ≥35 mmHg or hypoxemia on pulse oximetry (eg, room air oxygen saturation <92 percent) (Grade 2B). (See 'Adjunctive glucocorticoids' above.)

●Outcomes − The outcomes for immunocompromised patients without HIV who are treated for PCP are generally worse than in those with HIV; mortality from PCP in patients with HIV is approximately 10 to 20 percent compared with 35 to 50 percent in those without HIV. (See 'Outcomes' above.)

●Infection control − Hospitalized patients with PCP should be cared for using standard precautions, although they should not be placed in the same room with other immunocompromised individuals due to the potential for person-to-person spread. (See 'Infection control' above.)

●Prophylaxis

•Risk factors for PCP − PCP is a potentially life-threatening infection that occurs in immunocompromised individuals, especially in those with HIV but also in hematopoietic cell and solid organ transplant recipients, those with cancer (particularly hematologic malignancies), and those receiving glucocorticoids, chemotherapeutic agents, and other immunosuppressive medications. (See 'Introduction' above.)

•Indications for PCP prophylaxis

-We recommend PCP prophylaxis for the following high-risk groups: patients receiving a glucocorticoid dose equivalent to ≥20 mg of prednisone daily for one month or longer who also have another cause of immunocompromise; allogeneic hematopoietic cell transplant and solid organ transplant recipients; patients with acute lymphocytic leukemia; patients receiving certain immunosuppressive drugs (eg, rituximab, alemtuzumab, temozolomide in conjunction with radiotherapy, idelalisib); and selected autologous hematopoietic cell transplant recipients (Grade 1A). (See 'Indications' above.)

-PCP prophylaxis may also be indicated in other situations; these scenarios are discussed above. (See 'Indications' above.)

•Prophylaxis regimens − For most patients who require PCP prophylaxis, we recommend TMP-SMX (table 2) (Grade 1A). For patients with normal renal function, TMP-SMX may be given as one double-strength tablet daily or three times per week or as one single-strength tablet daily. Alternative regimens are discussed above. (See 'Regimens' above.)

Limper AH, Knox KS, Sarosi GA, et al. An official American Thoracic Society statement: Treatment of fungal infections in adult pulmonary and critical care patients. Am J Respir Crit Care Med 2011; 183:96.
Hughes WT, Feldman S, Sanyal SK. Treatment of Pneumocystis carinii pneumonitis with trimethoprim-sulfamethoxazole. Can Med Assoc J 1975; 112:47.
Lau WK, Young LS. Trimethoprim-sulfamethoxazole treatment of Pneumocystis carinii pneumonia in adults. N Engl J Med 1976; 295:716.
Winston DJ, Lau WK, Gale RP, Young LS. Trimethoprim-sulfamethoxazole for the treatment of Pneumocystis carinii pneumonia. Ann Intern Med 1980; 92:762.
Hughes WT, Feldman S, Chaudhary SC, et al. Comparison of pentamidine isethionate and trimethoprim-sulfamethoxazole in the treatment of Pneumocystis carinii pneumonia. J Pediatr 1978; 92:285.
Smego RA Jr, Nagar S, Maloba B, Popara M. A meta-analysis of salvage therapy for Pneumocystis carinii pneumonia. Arch Intern Med 2001; 161:1529.
Wazir JF, Ansari NA. Pneumocystis carinii infection. Update and review. Arch Pathol Lab Med 2004; 128:1023.
Kamboj M, Weinstock D, Sepkowitz KA. Progression of Pneumocystis jiroveci pneumonia in patients receiving echinocandin therapy. Clin Infect Dis 2006; 43:e92.
Limper AH, Offord KP, Smith TF, Martin WJ 2nd. Pneumocystis carinii pneumonia. Differences in lung parasite number and inflammation in patients with and without AIDS. Am Rev Respir Dis 1989; 140:1204.
Kovacs JA, Hiemenz JW, Macher AM, et al. Pneumocystis carinii pneumonia: a comparison between patients with the acquired immunodeficiency syndrome and patients with other immunodeficiencies. Ann Intern Med 1984; 100:663.
Wieruszewski PM, Barreto JN, Frazee E, et al. Early Corticosteroids for Pneumocystis Pneumonia in Adults Without HIV Are Not Associated With Better Outcome. Chest 2018; 154:636.
Delclaux C, Zahar JR, Amraoui G, et al. Corticosteroids as adjunctive therapy for severe Pneumocystis carinii pneumonia in non-human immunodeficiency virus-infected patients: retrospective study of 31 patients. Clin Infect Dis 1999; 29:670.
Ding L, Huang H, Wang H, He H. Adjunctive corticosteroids may be associated with better outcome for non-HIV Pneumocystis pneumonia with respiratory failure: a systemic review and meta-analysis of observational studies. Ann Intensive Care 2020; 10:34.
Pareja JG, Garland R, Koziel H. Use of adjunctive corticosteroids in severe adult non-HIV Pneumocystis carinii pneumonia. Chest 1998; 113:1215.
Yale SH, Limper AH. Pneumocystis carinii pneumonia in patients without acquired immunodeficiency syndrome: associated illness and prior corticosteroid therapy. Mayo Clin Proc 1996; 71:5.
Mansharamani NG, Garland R, Delaney D, Koziel H. Management and outcome patterns for adult Pneumocystis carinii pneumonia, 1985 to 1995: comparison of HIV-associated cases to other immunocompromised states. Chest 2000; 118:704.
Sepkowitz KA. Opportunistic infections in patients with and patients without Acquired Immunodeficiency Syndrome. Clin Infect Dis 2002; 34:1098.
Ward MM, Donald F. Pneumocystis carinii pneumonia in patients with connective tissue diseases: the role of hospital experience in diagnosis and mortality. Arthritis Rheum 1999; 42:780.
Sepkowitz KA, Brown AE, Telzak EE, et al. Pneumocystis carinii pneumonia among patients without AIDS at a cancer hospital. JAMA 1992; 267:832.
Festic E, Gajic O, Limper AH, Aksamit TR. Acute respiratory failure due to pneumocystis pneumonia in patients without human immunodeficiency virus infection: outcome and associated features. Chest 2005; 128:573.
Siegel JD, Rhinehart E, Jackson M, et al. 2007 Guideline for isolation precautions: Preventing transmission of infectious agents in healthcare settings, June 2007. http://www.cdc.gov/ncidod/dhqp/pdf/isolation2007.pdf (Accessed on July 02, 2008).
Stiehm ER, Ochs HD, Winkelstein JA. Immunodeficiency disorders: General considerations. In: Immunological Disorders in Infants and Children, 5th ed, Stiehm ER, Ochs HD, Winkelstein JA (Eds), Elsevier Saunders, Philadephia 2004. p.289.
Ochs HD, Stiehm ER, Winkelstein JA. Antibody deficiencies. In: Immunological Disorders in Infants and Children, 5th ed, Stiehm ER, Ochs HD, Winkelstein JA (Eds), Elsevier Saunders, Philadephia 2004. p.357.
National Comprehensive Cancer Network (NCCN) Clinical Practice Guidelines in Oncology. Prevention and treatment of cancer-related infections. Version 2.2014. http://www.nccn.org (Accessed on November 06, 2014).
Martin SI, Fishman JA, AST Infectious Diseases Community of Practice. Pneumocystis pneumonia in solid organ transplantation. Am J Transplant 2013; 13 Suppl 4:272.
Tomblyn M, Chiller T, Einsele H, et al. Guidelines for preventing infectious complications among hematopoietic cell transplantation recipients: a global perspective. Biol Blood Marrow Transplant 2009; 15:1143.
Huang L, Morris A, Limper AH, et al. An Official ATS Workshop Summary: Recent advances and future directions in pneumocystis pneumonia (PCP). Proc Am Thorac Soc 2006; 3:655.
Sepkowitz KA, Brown AE, Armstrong D. Pneumocystis carinii pneumonia without acquired immunodeficiency syndrome. More patients, same risk. Arch Intern Med 1995; 155:1125.
Thomas CF Jr, Limper AH. Pneumocystis pneumonia. N Engl J Med 2004; 350:2487.
Ognibene FP, Shelhamer JH, Hoffman GS, et al. Pneumocystis carinii pneumonia: a major complication of immunosuppressive therapy in patients with Wegener's granulomatosis. Am J Respir Crit Care Med 1995; 151:795.
Suryaprasad A, Stone JH. When is it safe to stop Pneumocystis jiroveci pneumonia prophylaxis? Insights from three cases complicating autoimmune diseases. Arthritis Rheum 2008; 59:1034.
Li J, Huang XM, Fang WG, Zeng XJ. Pneumocystis carinii pneumonia in patients with connective tissue disease. J Clin Rheumatol 2006; 12:114.
Meuli K, Chapman P, O'Donnell J, et al. Audit of pneumocystis pneumonia in patients seen by the Christchurch Hospital rheumatology service over a 5-year period. Intern Med J 2007; 37:687.
White ES, Lynch JP. Pharmacological therapy for Wegener's granulomatosis. Drugs 2006; 66:1209.
Zydelig. US Food and Drug Administration approved product information. Revised February 2018. US National Library of Medicine. https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=efbdafa9-d18c-4e85-b4a2-1e620fc74e50 (Accessed on March 19, 2018).
Lee R, Nayernama A, Jones SC, et al. Ibrutinib-associated Pneumocystis jirovecii pneumonia. Am J Hematol 2017; 92:E646.
Ahn IE, Jerussi T, Farooqui M, et al. Atypical Pneumocystis jirovecii pneumonia in previously untreated patients with CLL on single-agent ibrutinib. Blood 2016; 128:1940.
Rogers KA, Luay M, Zhao Q, et al. Incidence and type of opportunistic infections during ibrutinib treatment at a single academic center. Blood 2017; 130:830.
Temodar (temozolomide) for injection, prescribing information. http://www.merck.com/product/usa/pi_circulars/t/temodar_capsules/temodar_pi.pdf (Accessed on February 11, 2013).
US Food and Drug Administration. Highlights of prescribing information, CAMPATH (alemtuzumab). https://www.accessdata.fda.gov/drugsatfda_docs/label/2019/103948s5171lbl.pdf (Accessed on November 30, 2022).
Park JW, Curtis JR, Jun KI, et al. Primary Prophylaxis for Pneumocystis jirovecii Pneumonia in Patients Receiving Rituximab. Chest 2022; 161:1201.
Torisel Kit (temsirolimus) injection, for intravenous infusion, prescribing information. http://www.accessdata.fda.gov/drugsatfda_docs/label/2014/022088s016lbl.pdf (Accessed on October 13, 2014).
Kadoya A, Okada J, Iikuni Y, Kondo H. Risk factors for Pneumocystis carinii pneumonia in patients with polymyositis/dermatomyositis or systemic lupus erythematosus. J Rheumatol 1996; 23:1186.
Cooley L, Dendle C, Wolf J, et al. Consensus guidelines for diagnosis, prophylaxis and management of Pneumocystis jirovecii pneumonia in patients with haematological and solid malignancies, 2014. Intern Med J 2014; 44:1350.
National Comprehensive Cancer Network (NCCN) Clinical Practice Guidelines in Oncology. Prevention and Treatment of Cancer-Related Infection. Version 2.2016. https://oralcancerfoundation.org/wp-content/uploads/2016/09/infections.pdf (Accessed on August 02, 2022).
Taplitz RA, Kennedy EB, Bow EJ, et al. Antimicrobial Prophylaxis for Adult Patients With Cancer-Related Immunosuppression: ASCO and IDSA Clinical Practice Guideline Update. J Clin Oncol 2018; 36:3043.
Maertens J, Cesaro S, Maschmeyer G, et al. ECIL guidelines for preventing Pneumocystis jirovecii pneumonia in patients with haematological malignancies and stem cell transplant recipients. J Antimicrob Chemother 2016; 71:2397.
Classen AY, Henze L, von Lilienfeld-Toal M, et al. Primary prophylaxis of bacterial infections and Pneumocystis jirovecii pneumonia in patients with hematologic malignancies and solid tumors: 2020 updated guidelines of the Infectious Diseases Working Party of the German Society of Hematology and Medical Oncology (AGIHO/DGHO). Ann Hematol 2021; 100:1603.
Fishman JA, Gans H, AST Infectious Diseases Community of Practice. Pneumocystis jiroveci in solid organ transplantation: Guidelines from the American Society of Transplantation Infectious Diseases Community of Practice. Clin Transplant 2019; 33:e13587.
Tabanor JA, Lakshminarayanan S. Do patients on biologic drugs for rheumatic disease need PCP prophylaxis? Cleve Clin J Med 2019; 86:449.
Gonzalez Santiago TM, Wetter DA, Kalaaji AN, et al. Pneumocystis jiroveci pneumonia in patients treated with systemic immunosuppressive agents for dermatologic conditions: a systematic review with recommendations for prophylaxis. Int J Dermatol 2016; 55:823.
Park JW, Curtis JR, Moon J, et al. Prophylactic effect of trimethoprim-sulfamethoxazole for pneumocystis pneumonia in patients with rheumatic diseases exposed to prolonged high-dose glucocorticoids. Ann Rheum Dis 2018; 77:644.
Park JW, Curtis JR, Kim MJ, et al. Pneumocystis pneumonia in patients with rheumatic diseases receiving prolonged, non-high-dose steroids-clinical implication of primary prophylaxis using trimethoprim-sulfamethoxazole. Arthritis Res Ther 2019; 21:207.
Stern A, Green H, Paul M, et al. Prophylaxis for Pneumocystis pneumonia (PCP) in non-HIV immunocompromised patients. Cochrane Database Syst Rev 2014; :CD005590.
Langford CA, Talar-Williams C, Barron KS, Sneller MC. A staged approach to the treatment of Wegener's granulomatosis: induction of remission with glucocorticoids and daily cyclophosphamide switching to methotrexate for remission maintenance. Arthritis Rheum 1999; 42:2666.
Overgaard UM, Helweg-Larsen J. Pneumocystis jiroveci pneumonia (PCP) in HIV-1-negative patients: a retrospective study 2002-2004. Scand J Infect Dis 2007; 39:589.
Chung JB, Armstrong K, Schwartz JS, Albert D. Cost-effectiveness of prophylaxis against Pneumocystis carinii pneumonia in patients with Wegner's granulomatosis undergoing immunosuppressive therapy. Arthritis Rheum 2000; 43:1841.
Colby C, McAfee S, Sackstein R, et al. A prospective randomized trial comparing the toxicity and safety of atovaquone with trimethoprim/sulfamethoxazole as Pneumocystis carinii pneumonia prophylaxis following autologous peripheral blood stem cell transplantation. Bone Marrow Transplant 1999; 24:897.
Torre-Cisneros J, De la Mata M, Pozo JC, et al. Randomized trial of weekly sulfadoxine/pyrimethamine vs. daily low-dose trimethoprim-sulfamethoxazole for the prophylaxis of Pneumocystis carinii pneumonia after liver transplantation. Clin Infect Dis 1999; 29:771.

Topic 1393 Version 47.0

References

1 : An official American Thoracic Society statement: Treatment of fungal infections in adult pulmonary and critical care patients.

2 : Treatment of Pneumocystis carinii pneumonitis with trimethoprim-sulfamethoxazole.

3 : Trimethoprim-sulfamethoxazole treatment of Pneumocystis carinii pneumonia in adults.

4 : Trimethoprim-sulfamethoxazole for the treatment of Pneumocystis carinii pneumonia.

5 : Comparison of pentamidine isethionate and trimethoprim-sulfamethoxazole in the treatment of Pneumocystis carinii pneumonia.

6 : A meta-analysis of salvage therapy for Pneumocystis carinii pneumonia.

7 : Pneumocystis carinii infection. Update and review.

8 : Progression of Pneumocystis jiroveci pneumonia in patients receiving echinocandin therapy.

9 : Pneumocystis carinii pneumonia. Differences in lung parasite number and inflammation in patients with and without AIDS.

10 : Pneumocystis carinii pneumonia: a comparison between patients with the acquired immunodeficiency syndrome and patients with other immunodeficiencies.

11 : Early Corticosteroids for Pneumocystis Pneumonia in Adults Without HIV Are Not Associated With Better Outcome.

12 : Corticosteroids as adjunctive therapy for severe Pneumocystis carinii pneumonia in non-human immunodeficiency virus-infected patients: retrospective study of 31 patients.

13 : Adjunctive corticosteroids may be associated with better outcome for non-HIV Pneumocystis pneumonia with respiratory failure: a systemic review and meta-analysis of observational studies.

14 : Use of adjunctive corticosteroids in severe adult non-HIV Pneumocystis carinii pneumonia.

15 : Pneumocystis carinii pneumonia in patients without acquired immunodeficiency syndrome: associated illness and prior corticosteroid therapy.

16 : Management and outcome patterns for adult Pneumocystis carinii pneumonia, 1985 to 1995: comparison of HIV-associated cases to other immunocompromised states.

17 : Opportunistic infections in patients with and patients without Acquired Immunodeficiency Syndrome.

18 : Pneumocystis carinii pneumonia in patients with connective tissue diseases: the role of hospital experience in diagnosis and mortality.

19 : Pneumocystis carinii pneumonia among patients without AIDS at a cancer hospital.

20 : Acute respiratory failure due to pneumocystis pneumonia in patients without human immunodeficiency virus infection: outcome and associated features.

21 : Acute respiratory failure due to pneumocystis pneumonia in patients without human immunodeficiency virus infection: outcome and associated features.

22 : Acute respiratory failure due to pneumocystis pneumonia in patients without human immunodeficiency virus infection: outcome and associated features.

23 : Acute respiratory failure due to pneumocystis pneumonia in patients without human immunodeficiency virus infection: outcome and associated features.

24 : Acute respiratory failure due to pneumocystis pneumonia in patients without human immunodeficiency virus infection: outcome and associated features.

25 : Pneumocystis pneumonia in solid organ transplantation.

26 : Guidelines for preventing infectious complications among hematopoietic cell transplantation recipients: a global perspective.

27 : An Official ATS Workshop Summary: Recent advances and future directions in pneumocystis pneumonia (PCP).

28 : Pneumocystis carinii pneumonia without acquired immunodeficiency syndrome. More patients, same risk.

29 : Pneumocystis pneumonia.

30 : Pneumocystis carinii pneumonia: a major complication of immunosuppressive therapy in patients with Wegener's granulomatosis.

31 : When is it safe to stop Pneumocystis jiroveci pneumonia prophylaxis? Insights from three cases complicating autoimmune diseases.

32 : Pneumocystis carinii pneumonia in patients with connective tissue disease.

33 : Audit of pneumocystis pneumonia in patients seen by the Christchurch Hospital rheumatology service over a 5-year period.

34 : Pharmacological therapy for Wegener's granulomatosis.

35 : Pharmacological therapy for Wegener's granulomatosis.

36 : Ibrutinib-associated Pneumocystis jirovecii pneumonia.

37 : Atypical Pneumocystis jirovecii pneumonia in previously untreated patients with CLL on single-agent ibrutinib.

38 : Incidence and type of opportunistic infections during ibrutinib treatment at a single academic center

39 : Incidence and type of opportunistic infections during ibrutinib treatment at a single academic center

40 : Incidence and type of opportunistic infections during ibrutinib treatment at a single academic center

41 : Primary Prophylaxis for Pneumocystis jirovecii Pneumonia in Patients Receiving Rituximab.

42 : Primary Prophylaxis for Pneumocystis jirovecii Pneumonia in Patients Receiving Rituximab.

43 : Risk factors for Pneumocystis carinii pneumonia in patients with polymyositis/dermatomyositis or systemic lupus erythematosus.

44 : Consensus guidelines for diagnosis, prophylaxis and management of Pneumocystis jirovecii pneumonia in patients with haematological and solid malignancies, 2014.

45 : Consensus guidelines for diagnosis, prophylaxis and management of Pneumocystis jirovecii pneumonia in patients with haematological and solid malignancies, 2014.

46 : Antimicrobial Prophylaxis for Adult Patients With Cancer-Related Immunosuppression: ASCO and IDSA Clinical Practice Guideline Update.

47 : ECIL guidelines for preventing Pneumocystis jirovecii pneumonia in patients with haematological malignancies and stem cell transplant recipients.

48 : Primary prophylaxis of bacterial infections and Pneumocystis jirovecii pneumonia in patients with hematologic malignancies and solid tumors: 2020 updated guidelines of the Infectious Diseases Working Party of the German Society of Hematology and Medical Oncology (AGIHO/DGHO).

49 : Pneumocystis jiroveci in solid organ transplantation: Guidelines from the American Society of Transplantation Infectious Diseases Community of Practice.

50 : Do patients on biologic drugs for rheumatic disease need PCP prophylaxis?

51 : Pneumocystis jiroveci pneumonia in patients treated with systemic immunosuppressive agents for dermatologic conditions: a systematic review with recommendations for prophylaxis.

52 : Prophylactic effect of trimethoprim-sulfamethoxazole for pneumocystis pneumonia in patients with rheumatic diseases exposed to prolonged high-dose glucocorticoids.

53 : Pneumocystis pneumonia in patients with rheumatic diseases receiving prolonged, non-high-dose steroids-clinical implication of primary prophylaxis using trimethoprim-sulfamethoxazole.

54 : Prophylaxis for Pneumocystis pneumonia (PCP) in non-HIV immunocompromised patients.

55 : A staged approach to the treatment of Wegener's granulomatosis: induction of remission with glucocorticoids and daily cyclophosphamide switching to methotrexate for remission maintenance.

56 : Pneumocystis jiroveci pneumonia (PCP) in HIV-1-negative patients: a retrospective study 2002-2004.

57 : Cost-effectiveness of prophylaxis against Pneumocystis carinii pneumonia in patients with Wegner's granulomatosis undergoing immunosuppressive therapy.

58 : A prospective randomized trial comparing the toxicity and safety of atovaquone with trimethoprim/sulfamethoxazole as Pneumocystis carinii pneumonia prophylaxis following autologous peripheral blood stem cell transplantation.

59 : Randomized trial of weekly sulfadoxine/pyrimethamine vs. daily low-dose trimethoprim-sulfamethoxazole for the prophylaxis of Pneumocystis carinii pneumonia after liver transplantation.

Buy a Package

Treatment and prevention of Pneumocystis pneumonia in patients without HIV

References